Sulfonylurea

Phase 3Small molecule

Sanofi

Sulfonylurea is one of 196 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

195

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

HypoglycemiaActive, not recruiting

EpilepsyActive, not recruiting

Type 2 DiabetesActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

EpilepsyPreclinical

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Sulfonylurea

Sanofi

Phase 3

6 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Lovaza

AstraZeneca

Preclinical

1 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 7

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 8

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 9

Insulins

Eli Lilly

Preclinical

1 10

Sglt2i

UUniversity of Chicago

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus9 trials

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Completed· Sanofi logo

Sanofi·Phase 4·NCT02941367·184 enrolled

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT02111096·174 enrolled

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Completed· Sanofi logo

Sanofi·Phase 4·NCT02954692·112 enrolled

Show 6 more trials

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Terminated· Sanofi logo

Sanofi·Phase 3·NCT03761134·377 enrolled

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

Completed· Sanofi logo

Sanofi·Phase 3·NCT01169779·391 enrolled

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Completed· Takeda logo

Takeda·Phase 4·NCT01972724·114 enrolled

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Completed· GSK logo

GSK·Phase 3·NCT01777282·374 enrolled

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Completed·LLexicon Pharmaceuticals·Phase 3·NCT03066830·507 enrolled

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02532855·614 enrolled

Diabetes8 trials

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

Completed· GSK logo

GSK·Phase 3·NCT00379769·4,447 enrolled

Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)

Unknown status·HHaukeland University Hospital·Phase 4·NCT02624830·30 enrolled

Replication of the TECOS Diabetes Trial in Healthcare Claims

Completed·—··NCT03936062·349,476 enrolled

Show 5 more trials

Replication of the CARMELINA Diabetes Trial in Healthcare Claims

Completed·—··NCT03936036·101,830 enrolled

Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

Completed·HHaukeland University Hospital·Phase 4·NCT02624817·90 enrolled

Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

Completed·RRoyal Devon and Exeter NHS Foundation Trust·N/A·NCT00334711·50 enrolled

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

Unknown status·HHaukeland University Hospital·Phase 4·NCT04239586·30 enrolled

Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims

Completed·—··NCT03936023·182,126 enrolled

Type 2 Diabetes6 trials

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01340768·870 enrolled

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

Completed· Sanofi logo

Sanofi·Phase 3·NCT00713830·859 enrolled

The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes

Completed·UUniversity Hospital, Gentofte, Copenhagen·Phase 2·NCT00321321·12 enrolled

Show 3 more trials

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00395746·264 enrolled

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00866658·311 enrolled

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Completed·GGRADE Study Group·Phase 3·NCT01794143·7,850 enrolled

Cardiovascular Disease2 trials

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Completed·MMayo Clinic··NCT05214573·386,301 enrolled

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05102071

Observational Study1 trial

An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

Completed· Merck & Co. logo

Merck & Co.··NCT01357135·3,453 enrolled

8 more indications

Hypoglycemia1 trial

The OBSTACLE Hypoglycemia Study (MK-0000-158)

Completed· Merck & Co. logo

Merck & Co.··NCT00907881·1,069 enrolled

Epilepsy1 trial

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

Recruiting·RRoyal Devon and Exeter NHS Foundation Trust··NCT05751525·21 enrolled

MPA1 trial

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Completed·—·Phase 4·NCT03983551·101 enrolled

Double-blind1 trial

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Completed·PPhaseBio Pharmaceuticals Inc.·Phase 2·NCT01658501·593 enrolled

Chronic Kidney Disease1 trial

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Completed·WWeill Medical College of Cornell University··NCT03921242·4,888 enrolled

Type 2 Diabetic Patients1 trial

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Completed· Astellas logo

Astellas·Phase 3·NCT01242215·243 enrolled

Metformin1 trial

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

Completed· Novartis logo

Novartis·Phase 3·NCT01871558·42 enrolled

Unspecified2 trials

Januvia Re-examination Study (MK-0431-181)

Completed· Merck & Co. logo

Merck & Co.··NCT01062048·3,483 enrolled

Study of Sulphonylurea Synergy With DPP4 Inhibitors

Completed·UUniversity of Dundee·N/A·NCT04192292·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for Sulfonylurea. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfonylurea compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfonylurea. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Sulfonylurea

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes Mellitus9 trials

Diabetes8 trials

Type 2 Diabetes6 trials

Cardiovascular Disease2 trials

Observational Study1 trial

Hypoglycemia1 trial

Epilepsy1 trial

MPA1 trial

Double-blind1 trial

Chronic Kidney Disease1 trial

Type 2 Diabetic Patients1 trial

Metformin1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News